Palbociclib Drops 93% to ₹2,720. Roche’s ₹123,506 Vial Doesn’t Budge

On November 9, a 21-capsule pack of palbociclib from RPG Life Sciences drops from ₹40,421 to ₹2,720 in Indian pharmacies, a 93.3% cut ordered by the National Pharmaceutical Pricing Authority (NPPA). Roche’s originator bevacizumab, priced at ₹123,506 a vial, does not move a rupee, and that gap tells you exactly who the NPPA trade margin cap was built to hit.

How a 30% trade margin cap rewrote 543 cancer drug prices

On October 17, the NPPA invoked Paragraph 19 of the Drugs (Prices Control) Order 2013, the emergency clause for “extraordinary circumstances,” and applied trade margin rationalisation to 137 non-scheduled anti-cancer drugs. The rule is simple arithmetic. The trade margin can be no more than 30% of the MRP before GST, which means the shelf price can sit at most 42.86% above the price to stockist (PTS) that the manufacturer charged in March 2026.

On October 28, the Department of Pharmaceuticals published the first result: revised MRPs for 543 brands, effective November 9, with the list to grow as more companies file. The scope is wide. It covers any formulation containing one of the 137 molecules, single or in combination, and patented products are not exempt unless NPPA approves an exemption. The press release names denosumab, pegfilgrastim, bevacizumab and immunotherapies for more than 20 cancer types.

India has done this before. A 2019 pilot capped margins at 30% on 42 cancer drugs and cut prices on 526 brands by up to 90%. The 2026 version covers 3.3 times as many molecules, and it arrived with the Supreme Court pushing for more: on October 12, a bench questioned why the cap stopped at oncology and pointed to a domestic cardiac stent sold to retailers for about ₹5,000 with a ₹25,000 MRP.

Nine brands, nine price resets

The official release carried nine worked examples. Read the last column as “how many times the old price exceeded the new one.” Every one of these is a generic or biosimilar sold by an Indian company or local subsidiary, and the smallest multiple in the set is 2.3×.

Palbociclib took the deepest cut of the published examples, and no product in this set lost less than half its price.

Source: PIB, October 28, 2026 (nine brands); The South First and Angel One, October 29, 2026 (palbociclib). Percentages calculated by api-data.net.

The broader data look the same. The South First counted 643 product entries filed by manufacturers: 275 of them, or 42.8%, fell more than 50%, and 89 fell more than 75%. Of the 56 products priced above ₹100,000, only three were cut at all.

Why a ₹123,506 originator vial passed through untouched

The cap ignores how expensive a drug is and measures one thing: the gap between what the stockist pays and what the patient pays. A multinational brand that already sold close to a 30% trade margin has nothing to give back, while a generic that printed a high MRP to hand chemists and stockists a fat spread loses most of its sticker price overnight.

Angel One also reports pembrolizumab at about ₹2.16 lakh and the nivolumab brands of Bristol Myers Squibb India and Dr. Reddy’s unchanged. Our reading: those products were already inside the cap. Roche got no special treatment; its price structure simply had no padding for the formula to remove.

For bevacizumab, the reset produces a price ladder worth printing out. The biosimilar 400 mg vial that The News Mill tracked went from ₹42,000 to ₹13,136. The originator sits at 9.4 times that new price.

After November 9, a 400 mg bevacizumab biosimilar vial costs about one-ninth of the originator in India.

Source: The News Mill, October 28, 2026 (biosimilar 400 mg); Angel One and The South First, October 29, 2026 (originator).

Some of the old shelf prices were wild. Because the new MRP is set from the March 2026 stockist price, you can back out what the old MRP implied as a markup over PTS. It is an approximation that assumes the same GST on both prices, but the order of magnitude is hard to argue with.

A palbociclib pack that left the factory gate at roughly one-twentieth of its printed price tells you how the old distribution model worked. We saw the same logic in reverse when Medicare paid up to 17 times India’s semaglutide price: list prices in this business say more about who sits in the chain than about what the molecule costs to make.

Who gives up the margin, and who keeps it

Patients win first. BioSpectrum puts the expected saving at about ₹2,500 crore a year, against anti-neoplastic retail sales of ₹6,389 crore for the 12 months to September 2026, according to Pharmarack data in the same report. NPPA’s own justification, as quoted by The South First, is that cancer treatment “imposes a severe financial burden on patients.”

Stockists, chemists and hospital pharmacies pay. Hospitals are treated as stockists when they buy direct, so their spread on oncology drugs is now capped too. Analyst estimates cited by My Pharma Reviews put the hit at about 4% of EBITDA for Max Healthcare and 1–2% for other hospital chains, figures the author flags as needing company-level validation.

Manufacturers mostly keep their invoice price, because the formula starts from PTS and leaves it alone. What they lose is the MRP as a sales tool. A generic that won chemists by printing ₹40,421 on a pack the stockist bought for roughly one-twentieth of that now competes on the same 30% as everyone else. Multinationals with already-tight margins lose almost nothing, which is why the order reads, in practice, as a reset of the Indian generic trade rather than of Big Pharma pricing. We covered a similar pattern of value moving through a chain overnight in how sugammadex generics erased $353M from Bridion; here the regulator, not competition, does the erasing.

The case against the cap

The strongest objection concerns reach. India’s wide trade margins paid stockists and chemists to carry slow-moving, cold-chain oncology stock in smaller cities, and a uniform 30% treats a tier-3 chemist holding an oncology vial for a month the same as a metro hospital turning it over in a day. If carrying the product stops paying, availability thins out first where patients have the fewest options.

The order anticipates part of this. Manufacturers must keep production at current levels, need NPPA permission to cut monthly output, and must file Form IV at least six months before discontinuing a product. That protects supply volumes. It does not force anyone to stock them, and NPPA has also excluded patient assistance quantities from the price calculation, which patient groups quoted by Angel One have questioned. Our view: the cap is right on the numbers, and the six-month exit notice is the clause buyers should watch.

One last thought. For years the MRP on an Indian oncology generic told you what the chain could extract, not what the product was worth. From November 9, the stockist price shows through the label.

On November 9, India made cancer drugs no cheaper to produce, only much harder to overprice.